Antihypertensive therapy with adrenergic beta-receptor blockers and vasodilators

Aenishänslin, W; Pestalozzi-Kerpel, J.; Dubach, U. C.; Imhof, P; Turri, M

doi:10.1007/bf00561142

Cited by 22 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This confirms the results of other studies where hydrallazine has been found to be a useful addition to beta blocker-diuretic therapy in hypertension (Aenishanslin et aL, 1972;. The dosage of hydrallazine chosen in this study (25 mg three times daily) is unlikely to lead to the lupus erythematosus syndrome, since there is little correlation with this syndrome in patients receiving less than 300 mg/day (Alarcon-Segovia, Wakim, Worthington, 1967).…”

Section: Methodssupporting

confidence: 76%

“…* significantly lower than placebo, P < 0.05. Aenishanslin et al (1972) have reported that oxprenolol counteracts the rise in heart rate caused by vasodilatation with hydrallazine. Our findings confirm that the addition of hydrallazine to patients treated with oxprenolol does not result in a rise in heart rate, while the blood pressure lowering effect is maintained.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Hydrallazine or phentolamine as adjuncts to beta‐adrenoceptor blockade/thiazide therapy in hypertension.

Winchester¹,

Ward²,

McKillop³

et al. 1976

Brit J Clinical Pharma

View full text Add to dashboard Cite

1Ten patients not maximally controlled on an oxprenolol/cyclopenthiazide regimen for moderately severe hypertension were treated in a double blind crossover trial with either hydrallazine (75-150 mg/day) or phentolamine (60-120 mg/day) or placebo in addition to their other therapy. 2 Additional phentolamine therapy did not lower blood pressure significantly when compared with placebo. 3 Additional hydrallazine (75-150 mg/day) produced an approximate 10 mm, Hg fall in diastolic blood pressure, but no significant fall in systolic blood pressure. 4 Pulse rates did not alter with the addition of hydrallazine or phentolamine. 5 In patients who fail to attain optimal blood pressure response to ,B-adrenoceptor blocking drugs it is suggested that the addition of hydrallazine is a useful measure.

show abstract

Section: Methodssupporting

confidence: 76%

Section: Methodsmentioning

confidence: 99%

Hydrallazine or phentolamine as adjuncts to beta‐adrenoceptor blockade/thiazide therapy in hypertension.

Winchester¹,

Ward²,

McKillop³

et al. 1976

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Propranolol was demonstrated to block hydralazineinduced increases in serum renin activity in genetically hypertensive rats. We conclude that hypotensive potentiation of vasodilating drugs by propranolol in these animal models is mediated to a large extent by impair-INTRODUCTION When combined with propranolol, the vasodilatory drugs hydralazine and minoxidil yield an effective antihypertensive combination with few adverse effects (1)(2)(3)(4). Vasodilatory drugs induce renin release both in man (5)(6)(7) and in animals (8), and a large portion of this renin release can be blocked by propranolol in animals (8).…”

mentioning

confidence: 99%

Altered renin release and propranolol potentiation of vasodilatory drug hypotension.

Pettinger¹,

Keeton²

1975

J. Clin. Invest.

View full text Add to dashboard Cite

A B S T R A C T Vasodilating antihypertensive drugs induce hypotension with reflex tachycardia, renin release, and fluid and electrolyte retention. Propranolol can impair this renin release. The studies described here were designed to determine the hemodynamic role of vasodilatory drug-induced renin release and inhibition thereof by propranolol in two animals models, the unanesthetized, normotensive and the unanesthetized, genetically hypertensive rat. In studies with normotensive rats, propranolol impaired renin release and tachycardia resulting from hydralazine and minoxidil and potentiated their hypotensive action. Two additional interventions against the renin-angiotensin system were used in evaluating the mechanism of this potentiation. One was removal of the renin source by nephrectomy, and the second was blockade of angiotensin's vasoconstrictor action using a selective angiotensin antagonist, saralasin (1-Sar-8-Ala-angiotensin II [previously known as P-113]). Both interventions potentiated vasodilatory drug hypotension, as did propranolol, but did not prevent reflex tachycardia. When combined with saralasin propranolol did not add to protentiation by this peptide. A similar pattern of blood pressure decrement and potentiation was seen in genetically hypertensive rats when propranolol or saralasin treatment preceded hydralazine. Propranolol was demonstrated to block hydralazineinduced increases in serum renin activity in genetically hypertensive rats. We conclude that hypotensive potentiation of vasodilating drugs by propranolol in these animal models is mediated to a large extent by impair-

show abstract

“…The treatment of moderately severe hypertension can pose difficulties, as many effective blood pressure lowering agents are associated with troublesome side‐effects. With the advent of β‐receptor antagonists side‐effects have become less of a problem, and in hospital clinics a combination of diuretic, β‐blocker and vasodilator drugs has been shown to be effective in lowering blood pressure with relatively few side‐effects (Zacest et al, 1972, Aenishanslin et al, 1972).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of a Combination of Diuretic, β‐Blocker and Vasodilator in the Treatment of Hypertension in General Practice

Forrest

1978

Int J Clinical Practice

View full text Add to dashboard Cite

Antihypertensive therapy with adrenergic beta-receptor blockers and vasodilators

Cited by 22 publications

References 10 publications

Hydrallazine or phentolamine as adjuncts to beta‐adrenoceptor blockade/thiazide therapy in hypertension.

Hydrallazine or phentolamine as adjuncts to beta‐adrenoceptor blockade/thiazide therapy in hypertension.

Altered renin release and propranolol potentiation of vasodilatory drug hypotension.

Efficacy of a Combination of Diuretic, β‐Blocker and Vasodilator in the Treatment of Hypertension in General Practice

Contact Info

Product

Resources

About